Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Atara Biotherap (NQ: ATRA ) 7.870 -0.640 (-7.52%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 120,507 Open 8.550 Bid (Size) 7.900 (2) Ask (Size) 8.180 (4) Prev. Close 8.510 Today's Range 7.850 - 8.801 52wk Range 4.965 - 49.00 Shares Outstanding 101,102,152 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) September 06, 2024 From Atara Biotherapeutics, Inc. Via Business Wire Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference September 04, 2024 From Atara Biotherapeutics, Inc. Via Business Wire Performance YTD -34.40% -34.40% 1 Month +9.46% +9.46% 3 Month -11.57% -11.57% 6 Month -56.28% -56.28% 1 Year -80.08% -80.08% More News Read More Crude Oil Down 1%; Dollar Tree Shares Tumble After Downbeat Earnings September 04, 2024 Via Benzinga Exposures Fossil Fuels Atara Biotherapeutics (ATRA) Stock Is Up 20%: What's Going On? September 04, 2024 Via Benzinga Why GitLab Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket September 04, 2024 Via Benzinga Atara Biotherapeutics Announces $36 Million Registered Direct Offering September 03, 2024 From Atara Biotherapeutics, Inc. Via Business Wire ATRA Stock Earnings: Atara Biotherapeutics Misses EPS, Misses Revenue for Q2 2024 August 12, 2024 Via InvestorPlace Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update August 12, 2024 From Atara Biotherapeutics, Inc. Via Business Wire Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference August 07, 2024 From Atara Biotherapeutics, Inc. Via Business Wire Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease July 17, 2024 From Atara Biotherapeutics, Inc. Via Business Wire Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) July 05, 2024 From Atara Biotherapeutics, Inc. Via Business Wire Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum July 03, 2024 From Atara Biotherapeutics, Inc. Via Business Wire Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases June 21, 2024 From Atara Biotherapeutics, Inc. Via Business Wire Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session June 17, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's Intraday Session June 17, 2024 Via Benzinga Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split June 17, 2024 From Atara Biotherapeutics, Inc. Via Business Wire Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) June 07, 2024 From Atara Biotherapeutics, Inc. Via Business Wire Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference June 05, 2024 From Atara Biotherapeutics, Inc. Via Business Wire 12 Health Care Stocks Moving In Friday's After-Market Session May 31, 2024 Via Benzinga Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting May 29, 2024 From Atara Biotherapeutics, Inc. Via Business Wire Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA May 20, 2024 From Atara Biotherapeutics, Inc. Via Business Wire ATRA Stock Earnings: Atara Biotherapeutics Beats EPS, Beats Revenue for Q1 2024 May 09, 2024 Via InvestorPlace Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress May 09, 2024 From Atara Biotherapeutics, Inc. Via Business Wire 12 Health Care Stocks Moving In Tuesday's After-Market Session May 07, 2024 Via Benzinga Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) May 03, 2024 From Atara Biotherapeutics, Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
